Urinary Tract System

Benign Prostatic Hyperplasia

A benign enlargement of the prostate gland begins normally after age 50 probably secondary to the effects of male hormones. If significant enlargement occurs, it may pinch off the urethra making urination difficult or impossible. Though the prostate continues to grow during most of a man's life, the enlargement doesn't usually cause problems until late in life. BPH rarely causes symptoms before age 40, but more than half of men in their sixties and as many as 90 percent in their seventies and eighties have some symptoms of BPH.

Company Product Phase  
Impax Laboratories Inc. Tamsulosin hydrochloride PA Benign Prostatic Hyperplasia
Watson Pharmaceuticals Inc Rapaflo M Benign Prostatic Hyperplasia
Neurocrine Biosciences Inc NBI56418 III Benign Prostatic Hyperplasia
Allergan Inc Botox II Benign Prostatic Hyperplasia
Spectrum Pharmaceuticals Inc SPI153 II Benign Prostatic Hyperplasia

Erectile Dysfunction

Erectile Dysfunction (ED), also known as impotence, is the repeated inability to get or keep an erection for sexual intercourse. In 1998, breakthrough drug Viagra came on the market for the treatment of this condition. In older men, ED usually has a physical cause, such as disease, injury or side effects to other drugs. Any disorder that affects nerves or impairs blood flow has the potential to cause ED. ED is treatable at any age and more men have been seeking treatment and returning to normal sexual activity with improved treatments. An estimated 15 million to 30 million men are affected by ED.

Company Product Phase  
Allergan Inc Aphrodyne M Erectile Dysfunction
VIVUS Inc Muse M Erectile Dysfunction
SANAVITA ENTERPRISES, INC. Vasoderm M Erectile Dysfunction
VIVUS Inc Avanafil Erectile Dysfunction Erectile Dysfunction
Senetek Plc Invicorp III Erectile Dysfunction
VIVUS Inc TA1790 III Erectile Dysfunction

Hyperphosphatemia

Hyperphosphatemia is an electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood. Often, calcium levels are lowered (hypocalcemia) due to precipitation of phosphate with the calcium in tissues. It can be caused by hypoparathyroidism due to the lack of PTH effect of inhibiting renal reabsorption of phosophate. It is also commonly seen in chronic renal failure. High phosphate levels can be avoided with phosphate binders and dietary restriction of phosphate. This can also be caused by taking oral sodium phosphate solutions prescribed for bowel prepration for colonoscopy in children. Signs and symptoms include ectopic calcification, secondary hyperparathyroidism and renal osteodystrophy.

Company Product Phase  
Impax Laboratories Inc. Sevelamer carbonate PA Hyperphosphatemia
Impax Laboratories Inc. Sevelamer hydrochloride PA Hyperphosphatemia
Amgen Inc AMG223 II Hyperphosphatemia

Interstitial Cystitis

A chronic inflammatory condition of the bladder, the cause of interstitial cystitis is unknown and occurs more commonly in females. It is characterized by urinary frequency (as often as every 10 minutes), urgency, pressure and/or pain in the bladder and/or pelvis. Pain typically increases as the bladder fills and reduces after voiding. However some patients report pain with urination, often in the urethra.

Company Product Phase  
MediciNova Inc MN001 II Interstitial Cystitis
Watson Pharmaceuticals Inc Uracyst II Interstitial Cystitis
Urigen Pharmaceuticals Inc URG101 II Interstitial Cystitis

Urinary Incontinence

Urinary Incontinence (UI) is the accidental leaking of urine and is caused by muscles not functioning properly. Stress incontinence is a type of UI caused by sneezing, coughing, laughing, or other movements that put stress on the bladder and is the result of a weakening of the pelvic floor muscles, those which hold the urethra closed. Overactive bladder is also a type of UI and is caused by the involuntary contraction of bladder muscles. The female anatomy, along with the stresses of pregnancy and childbirth, make women much more likely to have UI than men. Many people are embarrassed about this problem and do not tell their doctor, though treatments are readily available. Urinary incontinence is quite common, affecting over 12 million adults.

Company Product Phase  
Watson Pharmaceuticals Inc Darifenacin hydrobromide PA Overactive Bladder
Impax Laboratories Inc. Tolterodine tartrate ER PA Overactive Bladder
Watson Pharmaceuticals Inc Trospium chloride PA Overactive Bladder
Impax Laboratories Inc Bethanechol chloride M Hypoactive bladder
Johnson & Johnson Ditropan XL (oxybutynin chloride) M Overactive Bladder
Watson Pharmaceuticals Inc Gelnique M Overactive Bladder
Watson Pharmaceuticals Inc Oxytrol M Overactive Bladder
Allergan Inc Sanctura M Overactive Bladder
Allergan Inc Sanctura XR M Overactive Bladder
BioForm Medical Inc Coaptite injectable implant M Urinary Incontinence
Impax Laboratories Inc Flavoxate Hydrochloride M Urinary Incontinence
Valeant Pharmaceuticals International Oxybutyn M Urinary Incontinence
Impax Laboratories Inc Oxybutynin chloride M Urinary Incontinence
Allergan Inc Botox III Overactive Bladder


©2010 BayBio All rights reserved. 400 Oyster Point Blvd. Suite 221, South San Francisco CA 94080 | Tel: (650) 871-7101 | www.BayBio.org built@zoomedia